Imatinib Completed Phase 2 Trials for Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00045669Imatinib Mesylate in Treating Patients With Salivary Gland Cancer